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spirin Resistance
n Underestimated Risk in
atients With Drug-Eluting Stents?*
ietmar Trenk, PHD, Franz-Josef Neumann, MD
ad Krozingen, Germany
or many years, dual antiplatelet therapy with aspirin and a
hienopyridine (ticlopidine or clopidogrel) has been the
ainstay of prevention of stent thrombosis after percutane-
us coronary intervention (PCI) with stent placement. In
he early days, the risk reduction by dual antiplatelet therapy
as so impressive that the variability of the antiplatelet
ffect received little attention. Nowadays, with the wide-
pread use of drug-eluting stents (DES), there is increased
eed for more effective and sustained antiplatelet therapy. It
as become clear that high residual platelet reactivity on
lopidogrel is associated with adverse events after coronary
tent placement (1–6).
See page 734
Compared with clopidogrel resistance, aspirin resistance,
o far, has received little attention in interventional cardi-
logy. In the field of primary or secondary prevention,
owever, the observation of recurrent events despite aspirin
reatment has raised the question early of whether these
reatment failures are caused by a defective action of aspirin
r by progression of disease despite an appropriate aspirin
ffect (7).
Aspirin inhibits the conversion of arachidonic acid (AA)
nto thromboxane A2 by the platelet through selective and
rreversible acetylation of a serine residue within cyclooxy-
enase [COX]-1 (8,9). The function of COX-1 is thereby
isabled for the lifespan of the platelet. An inhibition of
ore than 95% of the thromboxane-forming capacity is
equired for the antiplatelet efficacy of aspirin (10). Three
istinct types of aspirin resistance have been classified:
nsufficient bioavailability, including missing compliance,
nadequate dosing, or protection of COX-1 against acety-
ation by certain nonsteroidal anti-inflammatory drugs (type
, pharmacokinetic type); pharmacodynamic (“true”) resis-
ance caused by rare genetic changes in the COX-1 protein,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thed
merican College of Cardiology.
From Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany.isabling acetylation by aspirin, or acquired, transient over-
xpression of less aspirin-sensitive COX isoforms (type II);
nd heightened stimulation of platelets by aspirin-
nsensitive mechanisms (type III) (11).
Apart from direct measurement of serum thromboxane
2, various assays have been developed for ex vivo identifi-
ation of aspirin resistance. These include: urinary 11-
ehydrothromboxane B2 excretion, AA-stimulated expres-
ion of surface receptors, optical platelet aggregometry after
timulation with AA, and various assays measuring platelet
ggregation induced by other agonists. To a variable degree
he results of these assays are influenced by mechanisms
ther than aspirin resistance. Hence, there is only partial
verlap between the various tests and, in particular, with the
old standard, direct measurement of serum thromboxane
2. Depending on assay, cut-point, clinical setting, and
spirin dosage, putatively defective pharmacodynamic ac-
ion of aspirin is found in 1% to 65% of the patients (7).
n an investigation of 682 patients undergoing coronary
ngiography, Frelinger et al. (12) found aspirin resistance in
nly 2%, which always could be attributed to noncompli-
nce or underdosing. Consistently, Gurbel et al. (13) re-
orted aspirin resistance assessed by arachidonic acid-
nduced optical aggregometry in 2 of 125 stable outpatients
ith coronary artery disease while on 81 mg aspirin, but in
one at an aspirin dose of 325 mg.
Evidence linking clinical outcome to the results of ex vivo
ssays for aspirin resistance has been sparse. The strongest
vidence derives from a nested case-control study on 970
atients of the HOPE (Heart Outcomes Prevention Eval-
ation) study who had baseline measurements of urinary
1-dehydrothromboxane B2 (14). At 5-year follow-up,
atients with levels in the highest quartile had an almost
-fold increase in risk for cardiovascular death, myocardial
nfarction, and stroke. To our knowledge, the investigation
y Gori et al. (15), published in this issue of the Journal, is
he first to address the impact of ex vivo measures of aspirin
esistance on clinical outcome after PCI with DES.
Gori et al. (15) report a secondary analysis of the
reviously published RECLOSE (Low Responsiveness to
lopidogrel and Sirolimus- or Paclitaxel-Eluting Stent
hrombosis) trial (5) comprising 746 of the 804 patients of
he original RECLOSE study cohort. The RECLOSE
tudy primarily showed an association between the 6-month
isk of stent thrombosis after PCI with DES and clopi-
ogrel nonresponse. The current analysis also includes
spirin nonresponse, using a generally accepted definition
hat is platelet aggregation by arachidonic acid (1 mM)
20%. Aspirin nonresponse was found in 131 (17.5%)
atients, and one-third of them were also nonresponsive to
lopidogrel. Within the 6-month follow-up, the incidence
f stent thrombosis was significantly higher in dual nonre-
ponders than in the other patients (11.1% vs. 2.1%, p 
.001). Between lone aspirin nonresponders, lone clopi-
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.1%, respectively). On multivariable analysis, only the
nteraction term for aspirin and clopidogrel nonresponse,
ut not aspirin and clopidogrel nonresponse by themselves,
howed a significant independent association with stent
hrombosis. The investigators conclude that dual nonre-
ponsiveness to aspirin and clopidogrel identifies patients at
ery high risk of stent thrombosis after PCI with DES.
Two questions arise:
. What is the reason for the stunning difference in the
incidence of aspirin resistance between the RECLOSE
study cohort and other studies on cardiac patients?
. Do we still need clopidogrel in patients who respond
well to aspirin?
Based on recent studies on aspirin nonresponse in cardiac
atients, the expected incidence of aspirin resistance is
2%, whereas it was 17.5% in the RECLOSE study.
nderdosing cannot serve as an explanation because the
ECLOSE study administered a high dose of aspirin (325
g). However, there may be an issue with noncompliance,
articularly in the 43% of patients with delayed testing at
ay 6 after administration of abciximab. An important
ifference from previous studies on aspirin resistance is the
igh proportion of patients with acute coronary syndromes
n the RECLOSE study, with acute myocardial infarction
n 26.0% and unstable angina in 39.9% of the current
nalysis of patients. Platelets are highly activated in acute
oronary syndromes (16–18). Thus, it is conceivable that a
igh baseline platelet reactivity may have limited the ability
f any drug to achieve adequately low levels of platelet
eactivity (type III aspirin resistance). This interpretation is
upported by the observation in the RECLOSE study that
lopidogrel nonresponders were more likely to be aspirin
onresponders than clopidogrel responders and vice versa
odds ratio for dual nonresponse: 6.6 [95% confidence
nterval: 4.1 to 10.6]). In addition, there is the possibility
hat the increased platelet turnover in acute coronary syn-
romes may lead to the release of young platelets still able to
orm thromboxane A2 or to an overexpression of the aspirin-
nsensitive COX-2 isoform (type II aspirin resistance).
Concerning the second question, the finding in the
ECLOSE study that the stent thrombosis rate in respond-
rs to a single antiplatelet agent is similar to the event rate
n dual responders is puzzling. It may appear that clopi-
ogrel nonresponse does not matter and that single treat-
ent with aspirin may be sufficient when responsiveness is
onfirmed by laboratory testing. We have to realize, how-
ver, that the current analysis of the RECLOSE study
ohort did not have the power to support such conclusions.
he strong mechanistic interdependence of clopidogrel and
spirin nonresponse limits the ability to detect the indepen-
ent contribution of each of the 2 variables. Apart from the
act that the number of patients presenting with lone
onresponsiveness to either clopidogrel (n  45) or aspirin
n  86) is low, we have to consider that 58 of the patientsf the original RECLOSE study cohort were not included
n the current analysis. This resulted in 5 events less with
urther reduction of power. In addition, we cannot fully
xclude selection bias, because the event rate of patients not
ncluded was significantly higher than that of those included
8.6% vs. 2.7%, p  0.01). Therefore, the current analysis
oes not rule out an independent contribution of high
n-clopidogrel platelet reactivity to clinical outcome. In-
eed, multivariable analysis even of the current RECLOSE
tudy data set maintained a trend in this direction (adjusted
azard ratio for stent thrombosis of clopidogrel nonre-
ponse: 2.23 [95% confidence interval: 0.85 to 5.82, p 
.10]).
It is the merit of the current study to put aspirin resistance
n the map of interventional cardiology. Gori et al. (15)
emind us that nonresponse to aspirin is a neglected risk
fter PCI with DES, particularly when combined with
lopidogrel nonresponse. Ongoing large-scale studies, such
s the ADAPT-DES (Assessment of Dual Anti-Platelet
herapy with Drug-Eluting Stents) trial (19), will delineate
he incidence of abnormal ex vivo platelet responses to
spirin-sensitive stimuli in various patient subsets and will
eveal the clinical risks associated with such abnormalities.
eprint requests and correspondence: Dr. Dietmar Trenk,
erz-Zentrum Bad Krozingen, Suedring 15, D-79189 Bad Kroz-
ngen, Germany. E-mail: dietmar.trenk@herzzentrum.de.
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